Exact Sciences · 1 day ago
Business Development Intern - Summer 2026
Madison, WI
Internship
Onsite
Intern
$36K/yr - $57K/yr
Start in 2026 SummerExact Sciences is dedicated to changing how the world prevents, detects, and guides treatment for cancer. The Business Development Intern will work with the Precision Oncology team to gain hands-on experience in financial research and business development, focusing on market research and data analysis.
BiotechnologyHealth DiagnosticsManufacturingMedical
No H1B
Responsibilities
Research and evaluate companies / interesting technologies and provide report out to key personnel within the organization
Conduct secondary market research on current and future competitors and industry trends
Assist with research regarding technologies and assays associated with Exact Sciences’ Precision Oncology portfolio
Help analyze data for meaningful take-aways that can inform strategy
Build and analyze financial models as directed
Uphold company mission and values through accountability, innovation, integrity, quality, and teamwork
Support and comply with the company’s Quality Management System policies and procedures
Regular and reliable attendance
Qualification
Required
Currently enrolled in a bachelor's degree program in finance, accounting, or economics
Preference giving to candidates with a record of outstanding academic achievement
Basic proficiency with Microsoft Word and Excel
Authorization to work in the United States without sponsorship
Demonstrated ability to perform the essential duties of the position with or without accommodation
Benefits
Paid time off (including days for vacation, holidays, volunteering, and personal time)
Paid leave for parents and caregivers
A retirement savings plan
Wellness support
Health benefits including medical, prescription drug, dental, and vision coverage
Company
Exact Sciences
Exact Sciences offers a portfolio of cancer screening and diagnostic tests that span from early detection to treatment monitoring.
Founded in 1995
5001-10000 employees
Funding
Current Stage
Public CompanyTotal Funding
$2.75B2025-06-20Acquired
2024-04-11Post Ipo Debt· $620.7M
2023-02-23Post Ipo Debt· $500M
Leadership Team
Kevin Conroy
Chairman & CEO
Aaron Bloomer
Executive Vice President, CFO
Recent News
2026-01-23
legacy.thefly.com
2026-01-23
Company data provided by crunchbase